Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Disc Medicine, Inc. - Common Stock (NQ:IRON)

48.25 -0.64 (-1.31%)
Streaming Delayed Price Updated: 2:40 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Disc Medicine, Inc. - Common Stock

< Previous 1 2 3 Next >
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer
Dr. Rahul Rajan Kaushik is an accomplished technical operations leader with over two decades of expertise in Chemistry, Manufacturing and Controls (CMC) 
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory affairs 
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Underwritten Offering of Common Stock
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Participate in the Jefferies Global Healthcare Conference
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
From Disc Medicine Inc
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.